Citi Appointed Depositary Bank for Adaptimmune’s ADR Programme
May 19 2015 - 7:03AM
Business Wire
Citi’s Issuer Services business, acting through
Citibank N.A., has been appointed by Adaptimmune Therapeutics plc
(“Adaptimmune”), a clinical-stage biopharmaceutical company focused
on novel cancer immunotherapy products, as the depositary
bank for their Nasdaq listed American Depositary Receipt (ADR)
programme. Adaptimmune’s ADR programme trades on the Nasdaq Global
Select Market under the symbol “ADAP”.
“Citi is delighted to be appointed by Adaptimmune as depositary
bank for its Nasdaq listed ADR programme”, said Dirk Jones, Global
Head of Issuer Services, at Citi. “We are confident that we will be
able to assist Adaptimmune in expanding their investor outreach
through the support of our Investor Relations Advisory team and our
unparalleled equity distribution network.”
For more information on Citi’s Depositary Receipt Services,
visit www.citi.com/dr.
NOTES TO EDITORS
About Adaptimmune
Adaptimmune is a clinical stage biopharmaceutical company
focused on novel cancer immunotherapy products based on its T-cell
receptor platform. Established in 2008, the company aims to utilise
the body’s own machinery – the T cell – to target and destroy
cancerous cells by using engineered, increased affinity T cell
receptor (TCRs) as a means of strengthening natural patient T cell
responses. Adaptimmune’s lead program is an affinity enhanced
therapeutic targeting the NY-ESO cancer antigen. Its NY-ESO TCR
therapeutic candidate has demonstrated signs of efficacy and
tolerability in Phase 1/2 trials in solid tumors and in hematologic
cancer types. In June 2014, Adaptimmune announced that it had
entered into a strategic collaboration and licensing agreement with
GlaxoSmithKline for the development and commercialisation of the
NY-ESO TCR program. The company currently has over 100 employees.
For more information: http://www.adaptimmune.com
About Citi
Citi, the leading global bank, has approximately 200 million
customer accounts and does business in more than 160 countries and
jurisdictions. Citi provides consumers, corporations, governments
and institutions with a broad range of financial products and
services, including consumer banking and credit, corporate and
investment banking, securities brokerage, transaction services, and
wealth management.
Additional information may be found at www.citigroup.com |
Twitter: @Citi | YouTube: www.youtube.com/citi | Blog:
http://new.citi.com | Facebook: www.facebook.com/citi | LinkedIn:
www.linkedin.com/company/citi
View source
version on businesswire.com: http://www.businesswire.com/news/home/20150519006063/en/
Citi MediaCapucine Boncenne+44 (0) 20 7508
9355capucine.boncenne@citi.comorAdaptimmuneWill
RobertsVice President, Investor RelationsT: (215) 966-6264E:
will.roberts@adaptimmune.comorMargaret HenryHead of PRT: +44
(0)1235 430036Mob: +44 (0)7710 304249E:
margaret.henry@adaptimmune.com
Citigroup (NYSE:C)
Historical Stock Chart
From Aug 2024 to Sep 2024
Citigroup (NYSE:C)
Historical Stock Chart
From Sep 2023 to Sep 2024